The team from UAE were comprehensively outplayed throughout, with Anderson Talisca putting the home team in front in the 5th minute
football6 hours ago
India's drug regulator on Wednesday granted approval to Bharat Biotech for conducting late-stage trials of its nasal Covid-19 vaccine to be used as a booster shot, according to a Mint report, which cited ANI.
The vaccine maker submitted the late-stage trial application to the Drugs Controller General of India (DCGI) in December, adding that an intranasal vaccine as a booster dose will be easier to administer in mass vaccination campaigns.
The company had in August received the Drug Controller General of India's (DCGI's) nod for conducting phase 2 clinical trials of the nasal vaccine.
"DCGI's Subject Expert Committee has granted 'in principle' approval to Bharat Biotech for the conduct of 'Phase III superiority study and Phase III booster dose study' for its intranasal COVID vaccine and has asked it to submit protocols for approval," according to the report on Wednesday.
Bharat Biotech and DCGI did not immediately respond to Reuters requests for comment.
As a precautionary measure in light of rising Omicron coronavirus variant cases across the country, India approved the administration of Covid-19 booster shots on Christmas, with healthcare and frontline workers set to receive them from January 10.
The country is yet to approve the use of Bharat Biotech's intranasal vaccine, BBV154. In August, BBV154 received regulatory approval for mid- to late-stage trials. Local media had reported the mid-stage trial has completed.
India's inoculation drive so far has been dominated by a domestically produced version of the AstraZeneca Covid-19 shot by Serum Institute of India and Bharat Biotech's inactivated vaccine Covaxin, both administered through injections.
On Wednesday, the country reported 58,097 new coronavirus cases, twice the number seen only four days ago, taking its total caseload to over 35 million.
BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine. Bharat Biotech has in-licensed the technology from Washington University in St Louis, the US.
ALSO READ:
The company reports that the doses of the vaccine administered to healthy volunteers in the phase-1 clinical trial have been well tolerated. No serious adverse events were reported, the DBT had said.
The team from UAE were comprehensively outplayed throughout, with Anderson Talisca putting the home team in front in the 5th minute
football6 hours ago
Israel Katz was chosen for the post which is considered sensitive in light of Israel's current military operations in Gaza and Lebanon
mena8 hours ago
S&P Global UAE Purchasing Managers’ Index for October rises to 54.1
economy8 hours ago
While the UAE introduced a 9 per cent corporate income tax in 2023, Oman has proposed to levy income tax on the rich
business8 hours ago
In June, Vedas Marketing challenged the conclusions in the authority's decision by referring it to the Financial Markets Tribunal
business8 hours ago
Lender posts strong growth in total income by 17% year on year to Dh17 billion
finance8 hours ago
As the former CEO and Vice-President of Dubai Duty Free his influence on sport extended across global golf communities
sports8 hours ago
The country confirmed it is standing in solidarity with Egypt in this 'painful tragedy'
uae8 hours ago